Stomach Illness Statistics in US 2026 | Stomach Illness Facts

What is Stomach Illness?

Stomach illness — the umbrella term most Americans reach for when they feel nauseated, crampy, and rushing to the bathroom — covers an enormous range of gastrointestinal conditions, from the acute gastroenteritis that wipes you out for 48 hours to the chronic, lifelong burden of inflammatory bowel disease, peptic ulcer disease, gastric cancer, and the countless functional disorders that make everyday life unpredictable and painful. The stomach and its neighboring organs — the small intestine, colon, liver, and pancreas — form a system so central to human health that when it fails, the consequences ripple through everything else: nutrition, immunity, mood, productivity, and longevity. In the United States in 2026, stomach and gastrointestinal illnesses represent one of the largest, most costly, and most underappreciated public health burdens in the entire healthcare system. The authoritative “Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024”, published in Gastroenterology in May 2025, estimated that GI health care expenditures totaled $111.8 billion in 2021 — the most recent year with comprehensive data — and that GI diseases caused 281,413 deaths that same year, while generating 47.5 million ambulatory visits and 2.9 million hospitalizations. These numbers represent the daily, grinding reality of stomach illness in America.

What makes stomach illness in the US in 2026 such a pressing topic is the breadth of what falls within its scope. On one end of the spectrum sits acute gastroenteritis — the “stomach flu” — which generates hundreds of millions of episodes of illness every year, driven overwhelmingly by norovirus, the most contagious stomach illness pathogen known to science. In the 2024–2025 season, norovirus outbreaks surged to decade-high levels, with 2,407 reported US outbreaks between August 2024 and April 2025 — nearly double the 1,230 reported during the same period the prior season. On the other end sits stomach cancer (gastric cancer), where 31,510 new cases are estimated for 2026 by the American Cancer Society and where the 5-year survival rate remains just 37.9% — a sobering reflection of how late most diagnoses arrive. In between sits a vast, complex landscape of foodborne illness, peptic ulcer disease, H. pylori infection, IBD, GERD, and functional GI disorders — all of which are covered by the data in this article, all of which affect tens of millions of Americans every single year.

Interesting Key Facts About Stomach Illness in the US 2026

Source: CDC Norovirus Facts & NoroSTAT March 20, 2026; CDC Food Safety / Foodborne Illness Burden; USDA Economic Research Service Cost Estimates of Foodborne Illnesses 2025; Peery et al., “Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024,” Gastroenterology, May 2025; American Cancer Society Cancer Facts & Figures 2026; NCI SEER Cancer Stat Facts: Stomach Cancer 2025; CDC IBD Facts and Stats July 2024

Reading these facts alongside each other tells a story about stomach illness in America that is both startlingly large in scale and surprisingly underrecognized in public health conversations. The $74.7 billion annual economic cost of foodborne illness alone — calculated by the USDA’s Economic Research Service in their most recent 2025 update using 2023 dollars — dwarfs most other preventable illness categories, yet food safety infrastructure remains underfunded and fragmented. The $111.8 billion in annual GI healthcare expenditures in 2021 is a number that has likely grown further since, given medical cost inflation and the increasing prevalence of costly biologic therapies for IBD. Together, these figures establish that stomach illness is not a peripheral health concern — it is a central driver of American healthcare spending, workforce absenteeism, and years lived with disability.

The norovirus surge of the 2024–2025 season deserves particular attention because it signals where the immediate infectious risk stands heading into 2026. The emergence of the GII.17 variant, which caused 75% of norovirus outbreaks in the US in 2024–2025 compared to less than 10% in 2023, has created a population with limited immunity to the circulating strain — exactly the conditions under which epidemic-level spread occurs. As CDC’s NoroSTAT data through March 2026 shows the current 2025–2026 season tracking within historical norms, the broader trend of surging outbreak numbers post-COVID is a genuine public health concern. The combination of 19–21 million annual norovirus illnesses, 109,000 hospitalizations, and 900 deaths represents one of the most heavily burdening preventable illness categories in the United States.

Acute Gastroenteritis & Norovirus Statistics in the US 2026

Source: CDC Norovirus Facts & Statistics; CDC NoroSTAT Data, March 20, 2026; CDC Norovirus Outbreaks, March 9, 2026; NIH StatPearls Viral Gastroenteritis (Updated May 4, 2025); Emerging Infectious Diseases CDC journal, Vol. 28, No. 11, 2022; Today.com / CDC CaliciNet data, December 26, 2025

Acute gastroenteritis and norovirus statistics in 2026 frame a paradox that characterizes much of the stomach illness story in America: this is a condition that affects hundreds of millions of people, costs billions of dollars, and kills thousands of Americans every year — yet it receives comparatively little public attention or sustained prevention investment because most episodes resolve within 48–72 hours without medical care. The estimated 179 to 350 million annual acute gastroenteritis episodes in the US reflect genuine uncertainty in the true burden because, as CDC acknowledges, most people never seek medical care, never get tested, and therefore never enter any surveillance system. The FoodNet community surveys’ finding that Americans experience 0.7–1.4 stomach illness episodes per person per year means that virtually every American adult can expect to suffer at least one significant GI illness annually — a remarkable burden that tends to be normalized as simply “getting a stomach bug.”

The 2024–2025 norovirus season’s near-doubling of reported outbreaks is the most recent and most dramatic evidence that stomach illness surveillance demands ongoing vigilance. The GII.17 variant’s dominance — rising from less than 10% to 75% of circulating strains in a single year — illustrates how rapidly norovirus populations can shift, and why the “herd immunity” accumulated against older strains offers limited protection against a newly dominant one. Norovirus’s extraordinary transmissibility — as few as 10 to 100 viral particles sufficient to cause infection — combined with its resistance to common disinfectants including alcohol and quaternary ammonium compounds, makes outbreak prevention in close-contact settings like nursing homes, schools, cruise ships, and daycares an ongoing challenge regardless of hygiene improvements. The 900 annual deaths, concentrated in Americans over 65, underscore that what feels like a miserable but manageable inconvenience for healthy adults can be a life-threatening dehydration emergency for the elderly.

Foodborne Illness Statistics in the US 2026

Source: CDC Food Safety Burden of Foodborne Illness; USDA Economic Research Service Cost Estimates of Foodborne Illnesses 2025; Peery et al., Emerging Infectious Diseases, April 2025 (CDC); PIRG Education Fund “Food for Thought 2025” Report, February 2025; CIDRAP February 17, 2025; Food Safety News January–February 2025; GAO Food Safety Report January 2025

Foodborne illness statistics in the US in 2026 reveal a food safety system that is simultaneously sophisticated and strained. The $74.7 billion annual economic cost, updated by USDA economists using 2023 dollars in their most current 2025 estimates, represents the full cascade of illness from doctor visits to lost wages to long-term complications like kidney failure from E. coli O157:H7 infections. But what the cost figures alone cannot convey is the human experience captured in 2024’s outbreak data: a doubling of hospitalizations in a single year, deaths associated with deli meat, cucumbers, onions, carrots, soft cheese, and raw cheddar — the kinds of everyday foods that Americans consume without a second thought. The Boar’s Head Listeria outbreak — 61 sickened, 60 hospitalized, 10 suspected dead — was the largest Listeria outbreak in recent US history and exposed how quickly a single manufacturing failure can cascade into a national public health emergency.

The CDC’s estimate that for every confirmed Salmonella patient there are actually 29 more who are sick but never diagnosed is the statistical fact that frames everything else about foodborne illness surveillance. The 1,392 people confirmed sick in recalled-food outbreaks in 2024 are literally the tip of an iceberg — the fraction whose illness was severe enough, distinctive enough, and connected closely enough to a specific recalled product to appear in any official count. The tens of millions who get sick from food each year and recover at home, attributing their misery to “a stomach bug,” largely disappear from the data. This massive undercount means that every foodborne illness number cited from official sources should be understood as a minimum floor, not a ceiling — and that the true burden of stomach illness from contaminated food in America in 2026 is substantially larger than even the sobering numbers above suggest.

Gastrointestinal Disease Burden & Healthcare Use in the US 2026

Source: Peery AF et al., “Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024,” Gastroenterology 168(5):1000–1024, May 2025; CDC NCHS FastStats Digestive Diseases; Rome Foundation Global Epidemiology Study 2017–2018; CDC IBD Facts and Stats July 2024; Oshi Health GI Disease Report 2025

The gastrointestinal disease burden and healthcare utilization statistics published in the most comprehensive available report — the Gastroenterology Update 2024, published in May 2025 — constitute the gold-standard dataset for understanding what stomach illness costs America in aggregate. The 47.5 million ambulatory visits and 2.9 million hospitalizations for GI diagnoses annually dwarf most other disease categories, and the fact that emergency department visits for GI conditions run at approximately 5 times the hospitalization rate — meaning roughly 14–15 million ED visits — captures the acute, unpredictable nature of stomach illness that sends Americans to emergency rooms rather than scheduled appointments. The $174 billion in total inpatient charges represents one of the largest categories of hospital billing in the entire US healthcare system.

The finding that approximately 60% of US adults report having at least one frequent GI symptom in the past three months — from the Rome Foundation Global Epidemiology Study data included in the 2025 Gastroenterology update — is perhaps the most humanizing number in the entire dataset. It means stomach illness is not a condition that happens to an unlucky minority; it is a near-universal feature of American adult life. Six separate constipation or diarrhea symptoms were each reported to occur frequently by at least 1 in 5 individuals in the study. Ten additional GI symptoms — including bloating, heartburn, chest pain, and difficulty swallowing — were each experienced frequently by at least 1 in 10. When most Americans have regular, significant GI symptoms, the question of how to define “stomach illness” becomes less about diagnosis and more about the spectrum of digestive dysfunction that characterizes modern American life.

Stomach Cancer (Gastric Cancer) Statistics in the US 2026

Source: American Cancer Society, Cancer Facts & Figures 2026 (accessed December 2025); National Cancer Institute SEER Cancer Stat Facts: Stomach Cancer 2025; Medical News Today Stomach Cancer Survival Rate, updated July 8, 2025; PLOS One “Incidence trends of gastric cancer in the United States over 2000–2020,” September 2024

Stomach cancer statistics in the US in 2026 tell a story that is both encouraging and deeply concerning depending on which direction you look. The long-term trajectory is positive: overall incidence and death rates for gastric cancer have been declining in the US for decades, driven by improved refrigeration reducing consumption of salt-preserved foods, antibiotic treatment of H. pylori infection, and better early detection. The 37.9% five-year survival rate, while still low in absolute terms, represents meaningful improvement from the 18.8% five-year survival rate for patients diagnosed in 2000 — nearly doubling over two decades. When diagnosed at the localized stage, before the cancer spreads beyond the stomach, survival rates are substantially higher; the challenge is that most stomach cancers are not caught at the localized stage because early gastric cancer produces few specific symptoms, and the US does not have the kind of widespread endoscopic screening programs that Japan and South Korea use to achieve dramatically better detection rates.

The rising incidence among adults under 50 — increasing at +0.95% per year from 2000 to 2020 according to PLOS One’s 2024 SEER analysis — is the most alarming trend in the stomach cancer data. For a disease that predominantly strikes older Americans (average diagnosis age 68, with 60% of patients age 65 or older), the emergence of a younger-onset phenotype suggests changing risk factor exposures — diet, H. pylori infection patterns in younger generations, or other environmental factors — that warrant serious clinical and research attention. The estimated 31,510 new stomach cancer cases for 2026 from the American Cancer Society’s Cancer Facts & Figures 2026 report represents a slight upward revision from 2025 estimates, reflecting these demographic dynamics. With stomach cancer accounting for about 1.5% of all new US cancer diagnoses, it may seem small against the backdrop of breast and lung cancer, but for the ~10,740 Americans expected to die of it in 2026, it carries the full weight of one of the most survivable-if-caught-early conditions in oncology.

Peptic Ulcer Disease, IBD & Chronic Stomach Conditions in the US 2026

Source: CDC IBD Facts and Stats, Updated July 2024; CDC National Health Interview Survey / FastStats; The Global Statistics Digestive Disease Statistics US 2025; Clinical Gastroenterology and Hepatology prevalence and cost study; Oshi Health GI Disease in America 2025; Frontiers in Microbiology 2024; WHO H. pylori classification; IBS in America survey

Chronic stomach conditions in the US in 2026 impose a sustained, often invisible toll that differs fundamentally from the acute misery of gastroenteritis — these are lifelong diagnoses that reshape how patients eat, travel, work, and plan their lives. The 14.8 million Americans with diagnosed peptic ulcers — 5.9% of the adult population — suffer from painful sores in the stomach or small intestinal lining whose primary causes, H. pylori bacteria and NSAID use, are both treatable or preventable yet continue to generate enormous healthcare utilization. The 2.4–3.1 million Americans with IBD, living with Crohn’s disease or ulcerative colitis that typically strikes between the ages of 15 and 35, face a lifetime of disease management that averages $22,987 per person per year in direct medical costs alone — three times what non-IBD patients spend. With biologic therapies now the standard of care for moderate-to-severe IBD but costing tens of thousands of dollars annually, the economic burden of these conditions continues to climb steeply.

The roughly 4 years it takes the average IBS patient to receive a diagnosis — according to a 2015 patient survey cited in current 2025 clinical literature — illuminates a healthcare system failure that is still playing out today. Irritable bowel syndrome, affecting 10–15% of US adults and making it one of the most prevalent functional GI disorders in the country, produces no structural damage visible on endoscopy or imaging. Its diagnosis depends entirely on symptom patterns meeting Rome criteria, a framework that remains poorly understood by the approximately 72% of community gastroenterologists who still believe IBS requires a diagnosis of exclusion — running extensive, expensive tests to rule out everything else before accepting the diagnosis. This approach costs the US healthcare system hundreds of millions of dollars annually in unnecessary diagnostics while leaving patients in diagnostic limbo for years.

Stomach Illness Risk Factors, Prevention & Key Facts in the US 2026

Source: CDC Norovirus Facts; NIH StatPearls Viral Gastroenteritis, updated May 4, 2025; CDC Food Safety; USDA Economic Research Service Cost Estimates of Foodborne Illnesses 2025; Rome Foundation Global Epidemiology Study cited in Gastroenterology Update 2024; Today.com citing CDC CaliciNet December 2025; ACS / NCI Stomach Cancer Data

The stomach illness risk factor and prevention statistics for 2026 make a compelling case that much of the enormous burden documented throughout this article is preventable — but that prevention requires understanding which interventions actually work. The most actionable insight in the entire norovirus literature is that alcohol-based hand sanitizers are ineffective against norovirus; only soap-and-water handwashing removes the virus from hands. Given that hand sanitizer has become the default hygiene intervention in American offices, schools, and hospitals since 2020, and given that norovirus is the dominant cause of acute stomach illness, this gap between assumed and actual protection is operationally significant. Every hand sanitizer dispenser that replaces a soap-and-water station in a high-contact environment is, from a norovirus prevention standpoint, an exchange of effectiveness for convenience.

The Salmonella underdiagnosis multiplier of 29x and the E. coli multiplier of 26–106x are not quirky epidemiological footnotes — they are the quantitative expression of how invisibly vast the true stomach illness burden is in America. When the CDC estimates 48 million foodborne illness cases annually, most people visualize 48 million diagnosed, counted people. In reality, the 48 million is itself already an estimate of the actual population burden, derived by applying these multipliers to confirmed cases. The confirmed cases in surveillance systems represent a small fraction of the iceberg. This structural undercount matters enormously for policy: food safety resource allocation, recall response prioritization, and outbreak investigation capacity are all calibrated to a system that can only see a fraction of the illness it is meant to prevent.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE